Amino Acid, Peptide, or Protein
Zanidatamab Demonstrates Promising 30-Month Survival Rate in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Zanidatamab, HER2-positive, metastatic gastroesophageal adenocarcinoma, bispecific antibody, survival rate, gastric cancer, oncology.
Bristol Myers Advances Opdualag into Phase 3 Trials for First-Line Lung Cancer
Opdualag, Bristol Myers Squibb, lung cancer, first-line treatment, phase 3 trials, LAG-3/PD-1 combination therapy
ESMO24: AstraZeneca’s Imfinzi and Imjudo Combination Doubles 5-Year Overall Survival Rate in Advanced Liver Cancer
AstraZeneca, Imfinzi (durvalumab), Imjudo (tremelimumab), Advanced Liver Cancer, Unresectable Hepatocellular Carcinoma (HCC), 5-Year Overall Survival Rate, ESMO24
ESMO 2024: IO Biotech’s IO102-IO103 Vaccine in Combination with Pembrolizumab Shows Promising Results in Head and Neck Cancer
IO Biotech, IO102-IO103, Pembrolizumab (Keytruda), Head and Neck Cancer, ESMO Congress 2024, Therapeutic Cancer Vaccine, Immunotherapy
iTeos-GSK’s TIGIT Combination Demonstrates Superior Tumor Shrinkage in Phase 2 Trial
iTeos Therapeutics, GSK, TIGIT, EOS-448, Jemperli, Phase 2 trial, tumor shrinkage, immuno-oncology, cancer treatment
AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefits in Muscle-Invasive Bladder Cancer
AstraZeneca, Imfinzi (durvalumab), Muscle-Invasive Bladder Cancer (MIBC), Perioperative Treatment, Event-Free Survival (EFS), Overall Survival (OS), NIAGARA Phase III Trial
Roche Secures FDA Approval for Subcutaneous Ocrevus and Tecentriq, Lilly Gains Approval for Eczema Treatment
FDA approvals, Roche, Subcutaneous products, Ocrevus, Tecentriq, Lilly, Eczema treatment, Pharmaceutical industry, Biopharma news
KEYTRUDA (Pembrolizumab) Plus Chemoradiotherapy Reduces Mortality Risk by 33% in High-Risk Locally Advanced Cervical Cancer
KEYTRUDA (pembrolizumab), Chemoradiotherapy (CRT), High-risk locally advanced cervical cancer, Overall survival (OS), European Society for Medical Oncology (ESMO) Congress 2024
FDA Approves Roche’s Tecentriq Hybreza: First Subcutaneous PD-L1 Cancer Immunotherapy
Tecentriq Hybreza, Subcutaneous PD-L1 inhibitor, Cancer immunotherapy, FDA approval, Roche, Atezolizumab, Hyaluronidase-tqjs, Enhanze drug delivery technology
Roche Secures FDA Approval for Subcutaneous Tecentriq Hybreza, Enhancing Cancer Treatment Options
Roche, FDA Approval, Tecentriq Hybreza, Subcutaneous Administration, Cancer Immunotherapy, PD-L1 Inhibitor, Halozyme Therapeutics, Enhanze Drug Delivery Technology